For example, fibroblast-derived ECM abrogated anti-proliferative responses to BRAF/MEK inhibition in BRAFV600-mutated advanced melanoma and pharmacological targeting of key molecules could overcome drug resistance (50). This evidence concerns the gene MAP2K7 and melanoma.